CN1709249A - Pioglitazone soft capsule and its preparing method - Google Patents
Pioglitazone soft capsule and its preparing method Download PDFInfo
- Publication number
- CN1709249A CN1709249A CN 200510080362 CN200510080362A CN1709249A CN 1709249 A CN1709249 A CN 1709249A CN 200510080362 CN200510080362 CN 200510080362 CN 200510080362 A CN200510080362 A CN 200510080362A CN 1709249 A CN1709249 A CN 1709249A
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- preferred
- pioglitazone
- agent
- described soft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention relates to a pyrroletone soft capsule and its preparation method. The content of said soft capsule is solution type or suspension type made by mixing pyrroletone and one and/or several kinds of solubilization agent, solubility promoter, suspension adjuvant, solubilizing agent and surfactant and dissolving them, and said content can be used for preparing said soft capsule.
Description
Technical field
The present invention relates to pioglitazone soft capsule and preparation method thereof,, make the soft capsule that content is solution-type or suspension type by selection to its composition.
Background technology
Pioglitazone is a kind of thiazolidinediones euglycemic agent that is used for the treatment of type 2 diabetes mellitus.Mechanism of action is relevant with the existence of insulin, can reduce the insulin resistant of peripheral tissues and liver, increases the processing of the glucose that relies on insulin, and reduces the output of glycogen.It is by peroxide activator enzyme paraphyte activated receptor Y (PPAI-x), regulate transcribing of the multiple protein relevant with lipid metabolism with sugar, thereby amplified the Role in Plant Signal Transduction behind the Insulin receptor INSR in liver and the peripheral tissues, improved Blood glucose control, and do not stimulate secretion of insulin.Present good hypoglycemic activity, equally also can reduce the level of insulin, but do not destroy the negative feedback balance between blood glucose one insulin, be difficult for producing the hypoglycemia phenomenon.
At present existing pioglitazone peroral dosage form is tablet, capsule, and the disintegrate of solid orally ingestibles such as tablet, capsule is slow, absorption difference in the body, bioavailability are low.Soft capsule dosage form has been accelerated the process of disintegrate in the body, decomposition, stripping with respect to tablet, hard capsule, makes the easier absorption of active ingredient.
Summary of the invention
The present invention is intended to overcome problems such as the poor stability, the bioavailability that have the pioglitazone solid orally ingestible are low, has changed the dissolution and the low shortcoming of bioavailability of pioglitazone oral formulations, has improved curative effect.
Pioglitazone soft capsule of the present invention can prepare by the various appropriate method of soft capsule preparation, the preparation method of preferred pioglitazone soft capsule is as follows: one in pioglitazone and lytic agent, cosolvent, suspending agent, solubilizing agent, the surfactant and/or a plurality of mixed dissolution are made solution-type or suspension type content, adopt pressed film method to prepare soft capsule, soft capsule is through solidifying by cooling in wind, drying, wash ball, do eventually with appropriate solvent, promptly get product.
Pioglitazone soft capsule content described in the preparation method of the present invention composed as follows: form by pioglitazone and adjuvant.Wherein said adjuvant comprises in lytic agent, cosolvent, suspending agent, solubilizing agent, the surfactant one and/or a plurality of.Wherein lytic agent is Polyethylene Glycol, fish oil, soybean oil, refining Oleum Arachidis hypogaeae semen, Radix Oenotherae erythrosepalae oil, Herba Silybi mariani oil, Oleum Vitis viniferae, Oleum Helianthi, safflower oil, the Fructus Hippophae wet goods vegetable and animals oils of PEG400 or PEG600 liquid state, preferred PEG400 or soybean oil, the addition 10%--90% of lytic agent, preferably: 20-80%, more preferably: 30-70%; Cosolvent is mixture, pluronic F-68, zein, hydrogenated palm oil, soybean lecithin, lecithin, polyglycerol ester, sucrose fat of lower alcohols such as propylene glycol, glycerol, isopropyl alcohol and/or several alcohol etc., preferred propylene glycol or hydrogenated palm oil, the addition of cosolvent is 1%--50%, preferably: 5-45%, more preferably: 10-40%; Solubilizing agent is ethanol or hydroxypropyl, preferred hydroxypropyl, and the solubilizing agent addition is 0.1%--20%, and is preferred: 0.5%-15%, more preferably: 1%-10%; Suspending agent is the solid-state Polyethylene Glycol of PEG4000, PEG6000, liquid paraffin, lanoline, Cera Flava, glyceryl monostearate, high fatty alcohol, preferred PEG6000 or Cera Flava, addition is 1%～10%, and is preferred: 1.5%-8%, more preferably: 2%-6%; Surfactant is sorbester p17, sorbester p18, Tween 80, polysorbate60, sodium lauryl sulphate, neutral liquid fat, preferred neutral liquid fat, and the addition of surfactant is 1%～30% preferred: 3%-25%, more preferably: 5-20%; Wherein the content of pioglitazone is 1%～20%, and is preferred: 2-15%, more preferably: 3-10%; Each component sum of content is 100%.It is primary raw material that softgel shell adopts gelatin, glycerol and/or sorbitol etc., can add 0.2～0.8% titanium dioxide and make as opacifier.
The specific embodiment:
Pioglitazone soft capsule of the present invention can prepare by the various appropriate method of soft capsule preparation, preferably make: get pioglitazone by being prepared as follows method, lytic agent (the Polyethylene Glycol of PEG400 or PEG600 liquid state, fish oil, soybean oil, refining Oleum Arachidis hypogaeae semen, Radix Oenotherae erythrosepalae oil, Herba Silybi mariani oil, Oleum Vitis viniferae, Oleum Helianthi, safflower oil, Fructus Hippophae wet goods vegetable and animals oils, preferred PEG400 or soybean oil), cosolvent (propylene glycol, glycerol, the mixture of lower alcohols such as isopropyl alcohol and/or several alcohol, pluronic F-68, zein, hydrogenated palm oil, soybean lecithin, lecithin, polyglycerol ester, sucrose fat etc., preferred propylene glycol or hydrogenated palm oil), solubilizing agent (ethanol or hydroxypropyl, preferred hydroxypropyl), suspending agent (PEG4000, the Polyethylene Glycol that PEG6000 is solid-state, liquid paraffin, lanoline, Cera Flava, glyceryl monostearate, high fatty alcohol, preferred PEG6000 or Cera Flava), surfactant (sorbester p17, sorbester p18, Tween 80, polysorbate60, sodium lauryl sulphate, neutral liquid fat, preferred neutral liquid fat) in one and/or a plurality of mixed dissolution make solution-type or suspension type content; Get gelatin, purified water, the abundant mixing of glycerol and get glue, it is standby to regulate the adhesive tape that is compressed to 0.5-2.0mm thickness by press; Adopt pressed film method to prepare soft capsule,, wash ball, do eventually, promptly with appropriate solvent through solidifying by cooling in wind, drying.Enumerate several embodiment that are used to that the invention process process is described rather than are used for limiting protection domain, as follows:
Embodiment 1)
Soybean oil 390g
Pioglitazone 10g
Zein 35g
Tween 80 15g
Granulate 1000
Softgel shell glue prescription:
Gelatin: glycerol: water=1: 0.6: 0.7
The soft capsule that adopts above prescription to adopt preparation method to make, through study of pharmacy influence factor test, it is as follows to investigate the result:
| The investigation factor | Appearance character | Disintegration (min) | Content (%) |
| 0 day | Oval soft capsule | ??14 | ??98.3 |
| High temperature 10 days | Oval soft capsule | ??12 | ??99.1 |
| High humidity 10 days | Oval soft capsule | ??13 | ??99.2 |
| High light 10 days | Oval soft capsule | ??15 | ??98.9 |
Conclusion: investigate through high temperature, high humidity, high light condition effect factor, this product visual examination no change, disintegration time and content are all stable.
Embodiment 2)
PEG400?????????????342g
Pioglitazone 12g
Isopropyl alcohol 31g
Ethanol 15g
Granulate 1000
Softgel shell glue prescription:
Gelatin: sorbitol: water :=1: 0.6: 0.7
The soft capsule that adopts above prescription to adopt preparation method to make, through study of pharmacy influence factor test, it is as follows to investigate the result:
| The investigation factor | Appearance character | Disintegration (min) | Content (%) |
| 0 day | Oval soft capsule | ??15 | ??98.9 |
| High temperature 10 days | Oval soft capsule | ??13 | ??99.1 |
| High humidity 10 days | Oval soft capsule | ??14 | ??98.7 |
| High light 10 days | Oval soft capsule | ??15 | ??99.2 |
Conclusion: investigate through high temperature, high humidity, high light condition effect factor, this product visual examination no change, disintegration time and content are all stable.
Embodiment 3)
PEG600????????????????327g
Pioglitazone 15g
Propylene glycol 30g
Hydroxypropyl 28g
Granulate 1000
Softgel shell glue prescription:
Gelatin: sorbitol: water=1: 0.5: 0.8
The soft capsule that adopts above prescription to adopt preparation method to make, through study of pharmacy influence factor test, it is as follows to investigate the result:
| The investigation factor | Appearance character | Disintegration (min) | Content (%) |
| 0 day | Oval soft capsule | ??13 | ??99.1 |
| High temperature 10 days | Oval soft capsule | ??15 | ??98.9 |
| High humidity 10 days | Oval soft capsule | ??13 | ??98.7 |
| High light 10 days | Oval soft capsule | ??14 | ??98.8 |
Conclusion: investigate through high temperature, high humidity, high light condition effect factor, this product visual examination no change, disintegration time and content are all stable.
Embodiment 4)
Refining Oleum Arachidis hypogaeae semen 380g
Pioglitazone 25g
Hydrogenated palm oil 26g
Liquid paraffin 19g
Neutral liquid fat 30g
Granulate 1000
Softgel shell glue prescription:
Gelatin: glycerol: water=1: 0.4: 0.9
The soft capsule that adopts above prescription to adopt preparation method to make, through study of pharmacy influence factor test, it is as follows to investigate the result:
| The investigation factor | Appearance character | Disintegration (min) | Content (%) |
| 0 day | Oval soft capsule | ??15 | ??99.0 |
| High temperature 10 days | Oval soft capsule | ??13 | ??98.7 |
| High humidity 10 days | Oval soft capsule | ??14 | ??98.8 |
| High light 10 days | Oval soft capsule | ??13 | ??99.2 |
Conclusion: investigate through high temperature, high humidity, high light condition effect factor, this product visual examination no change, disintegration time and content are all stable.
Embodiment 5)
Herba Silybi mariani oil 385g
Pioglitazone 12g
Hydrogenated palm oil 37g
Neutral liquid fat 16g
Granulate 1000
Softgel shell glue prescription:
Gelatin: sorbitol: water :=1: 0.6: 0.7
The soft capsule that adopts above prescription to adopt preparation method to make, through study of pharmacy influence factor test, it is as follows to investigate the result:
| The investigation factor | Appearance character | Disintegration (min) | Content (%) |
| 0 day | Oval soft capsule | ??13 | ??98.9 |
| High temperature 10 days | Oval soft capsule | ??14 | ??99.2 |
| High humidity 10 days | Oval soft capsule | ??13 | ??99.0 |
| High light 10 days | Oval soft capsule | ??15 | ??98.6 |
Conclusion: investigate through high temperature, high humidity, high light condition effect factor, this product visual examination no change, disintegration time and content are all stable.
3, the stripping characteristics according to the pioglitazone soft capsule of this prepared are as follows:
Compare with existing preparation pioglitazone sheet, capsule dissolution:
| Sample time (min) | ??5 | ??10 | ??20 | ??30 | ??45 | ??60 |
| The pioglitazone sheet | ??23.1 | ??59.6 | ??88.3 | ??90.2 | ??96.9 | ??98.9 |
| The pioglitazone capsule | ??39.3 | ??66.8 | ??90.5 | ??91.9 | ??97.3 | ??99.1 |
| Pioglitazone soft capsule | ??45.8 | ??74.9 | ??92.6 | ??96.57 | ??99.7 | ??99.8 |
Conclusion: the dissolution of pioglitazone soft capsule agent is better than sheet, capsule, the dissolution rate height.
Claims (11)
1. a pioglitazone soft capsule is characterized in that content contains pioglitazone and other adjuvants.
2. the described soft capsule of claim 1 is characterized in that content is solution-type, suspension type.
3. the described soft capsule of claim 1, wherein said adjuvant comprise in lytic agent, cosolvent, suspending agent, solubilizing agent, the surfactant one and/or a plurality of.
4. the described soft capsule of claim 3, wherein said lytic agent is liquid polyethylene glycol and/or vegetable and animals oils.
5. the described soft capsule of claim 4, wherein said lytic agent is Polyethylene Glycol, fish oil, soybean oil, refining Oleum Arachidis hypogaeae semen, Radix Oenotherae erythrosepalae oil, Herba Silybi mariani oil, Oleum Vitis viniferae, Oleum Helianthi, safflower oil, the Fructus Hippophae wet goods vegetable and animals oils of PEG400 or PEG600 liquid state, preferred PEG400 or soybean oil.The addition 10%--90% of lytic agent, preferred: 20-80%, more preferably: 30-70%.
6. each described soft capsule of claim 1-5, wherein said cosolvent is the mixture, pluronic F-68, zein, hydrogenated palm oil, soybean lecithin, lecithin, polyglycerol ester, sucrose fat of lower alcohols such as propylene glycol, glycerol, isopropyl alcohol and/or several alcohol etc., preferred propylene glycol or hydrogenated palm oil.The addition of cosolvent is 1%--50%, and is preferred: 5-45%, more preferably: 10-40%.
7. each described soft capsule of claim 1-6, wherein said solubilizing agent is ethanol or hydroxypropyl, preferred hydroxypropyl; The solubilizing agent addition is 0.1%--20%, and is preferred: 0.5%-15%, more preferably: 1%-10%.
8. each described soft capsule of claim 1-7, wherein said suspending agent is the solid-state Polyethylene Glycol of PEG4000, PEG6000, liquid paraffin, lanoline, Cera Flava, glyceryl monostearate, high fatty alcohol, preferred PEG6000 or Cera Flava; Addition is 1%～10%, and is preferred: 1.5%-8%, more preferably: 2%-6%.
9. each described soft capsule of claim 1-8, wherein said surfactant is sorbester p17, sorbester p18, Tween 80, polysorbate60, sodium lauryl sulphate, neutral liquid fat, preferred neutral liquid fat, the addition of surfactant is 1%～30% preferred: 3%-25%, more preferably: 5-20%.
10. each described soft capsule of claim 1-9, the content of wherein said pioglitazone is 1%～20%, and is preferred: 2-15%, more preferably: 3-10%.
11. each described preparation of soft capsule method of claim 1-10, with one in pioglitazone and lytic agent, cosolvent, solubilizing agent, suspending agent, the surfactant and/or a plurality of, mixed dissolution makes solution-type or suspension type content, the preparation soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100803627A CN1311825C (en) | 2005-07-04 | 2005-07-04 | Pioglitazone soft capsule and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100803627A CN1311825C (en) | 2005-07-04 | 2005-07-04 | Pioglitazone soft capsule and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1709249A true CN1709249A (en) | 2005-12-21 |
| CN1311825C CN1311825C (en) | 2007-04-25 |
Family
ID=35705582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100803627A Expired - Fee Related CN1311825C (en) | 2005-07-04 | 2005-07-04 | Pioglitazone soft capsule and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1311825C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657626A (en) * | 2012-05-23 | 2012-09-12 | 重庆康刻尔制药有限公司 | Medicinal composite tablet of pioglitazone medicine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327833C (en) * | 2003-12-18 | 2007-07-25 | 华东中药工程集团有限公司 | Hawthorn leave flavone capsules and their preparing method |
-
2005
- 2005-07-04 CN CNB2005100803627A patent/CN1311825C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657626A (en) * | 2012-05-23 | 2012-09-12 | 重庆康刻尔制药有限公司 | Medicinal composite tablet of pioglitazone medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1311825C (en) | 2007-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1281356A (en) | Quickly soluble solid preparations | |
| CN1939358A (en) | Sarcandra glaber dispersant tablets | |
| CN109567173A (en) | A kind of Spirulin composition, spirulina disintegrating tablet and preparation method thereof | |
| CN1857264A (en) | Medicine composition with pioglitazone hydrochloride and glimepiride as active components and its preparing method and use | |
| CN101744788B (en) | Omeprazole enteric coated tablet and preparation method thereof | |
| CN101053565A (en) | Vaginal tablets containing coltrimazole | |
| CN1709249A (en) | Pioglitazone soft capsule and its preparing method | |
| CN1939399A (en) | Blood stream-breaking dispersing tablets | |
| CN1765363A (en) | Naftopidil soft capsule and its preparation method | |
| CN1709242A (en) | Glime piride soft capsule and its preparing method | |
| CN1709231A (en) | Tolterodine tartrate soft capsule and its preparing method | |
| CN101757076B (en) | Turnip seed chewable tablet | |
| CN1895250A (en) | Gliquilone slow-releasing preparation | |
| CN1698614A (en) | Gatifloxacin soft capsule and preparation method thereof | |
| CN1939407A (en) | Dispersant tablets of honeysuckle flower and coptis | |
| CN1490000A (en) | Hippophae rhamnoide flavone drops and preparation thereof | |
| CN1768758A (en) | Soft capsule of medicinal composition and its preparation method | |
| CN1823755A (en) | Nateglinide soft capsule and its preparation method | |
| CN1813708A (en) | Amiodarone hydro chloride dispensible tablet, and its preparing method | |
| CN100336505C (en) | Soybean aglycone soft capsule and its preparing method | |
| CN1698642A (en) | Baicalin soft capsule and preparation method thereof | |
| CN1679669A (en) | Polygala dropping balls and preparation thereof | |
| CN1309376C (en) | Musk slow-controlled release preparation and preparation method thereof | |
| CN1778293A (en) | Rutin effervesce agent composition | |
| CN1768743A (en) | Telmisartan soft capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070425 |